Advanced search
1 file | 240.61 KB Add to list

Surgery in mesothelioma: where do we go after MARS?

(2013) JOURNAL OF THORACIC ONCOLOGY. 8(5). p.525-529
Author
Organization
Abstract
The role of surgery in the management of malignant pleural mesothelioma remains controversial. Surgical resection consists of different procedures for diagnostic or therapeutic reasons. The latter includes either an extrapleural pleuropneumonectomy (EPP) or lung-sparing operations like debulking of the parietal and visceral pleura by pleurectomy/decortication (P/D) or extended pleurectomy/decortication, in which further debulking of the diaphragm or pericardium is included. Because of the modest outcome of surgery as single-modality therapy, combinations of chemotherapy, surgery, and radiation therapy were initiated as a new treatment strategy to improve prognosis. The observations that patients treated with P/D had an equal to better outcome than those treated with EPP, and that EPP with perioperative chemotherapy was better than EPP alone, raises the issue whether performing a P/D with perioperative chemotherapy would result in a further improvement of outcome with a lower operative mortality than with EPP and perioperative chemotherapy. This is the rationale for the next European Organisation for Research and Treatment of Cancer trial exploring the feasibility of P/D with perioperative chemotherapy.
Keywords
Multimodality treatment, Lung-sparing procedures, MALIGNANT-PLEURAL-MESOTHELIOMA, EXTRAPLEURAL PNEUMONECTOMY, Extended pleurectomy/decortication, Malignant pleural mesothelioma, Extrapleural pleuropneumonectomy, PROGNOSTIC-FACTORS, LUNG-CANCER, INTERNATIONAL-ASSOCIATION, SURGICAL-MANAGEMENT, TRIMODALITY THERAPY, MULTICENTER TRIAL, PHASE-III, PLEURECTOMY/DECORTICATION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 240.61 KB

Citation

Please use this url to cite or link to this publication:

MLA
Hiddinga, Birgitta I., and Jan Van Meerbeeck. “Surgery in Mesothelioma: Where Do We Go after MARS?” JOURNAL OF THORACIC ONCOLOGY, vol. 8, no. 5, 2013, pp. 525–29, doi:10.1097/JTO.0b013e31828353d7.
APA
Hiddinga, B. I., & Van Meerbeeck, J. (2013). Surgery in mesothelioma: where do we go after MARS? JOURNAL OF THORACIC ONCOLOGY, 8(5), 525–529. https://doi.org/10.1097/JTO.0b013e31828353d7
Chicago author-date
Hiddinga, Birgitta I, and Jan Van Meerbeeck. 2013. “Surgery in Mesothelioma: Where Do We Go after MARS?” JOURNAL OF THORACIC ONCOLOGY 8 (5): 525–29. https://doi.org/10.1097/JTO.0b013e31828353d7.
Chicago author-date (all authors)
Hiddinga, Birgitta I, and Jan Van Meerbeeck. 2013. “Surgery in Mesothelioma: Where Do We Go after MARS?” JOURNAL OF THORACIC ONCOLOGY 8 (5): 525–529. doi:10.1097/JTO.0b013e31828353d7.
Vancouver
1.
Hiddinga BI, Van Meerbeeck J. Surgery in mesothelioma: where do we go after MARS? JOURNAL OF THORACIC ONCOLOGY. 2013;8(5):525–9.
IEEE
[1]
B. I. Hiddinga and J. Van Meerbeeck, “Surgery in mesothelioma: where do we go after MARS?,” JOURNAL OF THORACIC ONCOLOGY, vol. 8, no. 5, pp. 525–529, 2013.
@article{4218311,
  abstract     = {{The role of surgery in the management of malignant pleural mesothelioma remains controversial. Surgical resection consists of different procedures for diagnostic or therapeutic reasons. The latter includes either an extrapleural pleuropneumonectomy (EPP) or lung-sparing operations like debulking of the parietal and visceral pleura by pleurectomy/decortication (P/D) or extended pleurectomy/decortication, in which further debulking of the diaphragm or pericardium is included. Because of the modest outcome of surgery as single-modality therapy, combinations of chemotherapy, surgery, and radiation therapy were initiated as a new treatment strategy to improve prognosis. The observations that patients treated with P/D had an equal to better outcome than those treated with EPP, and that EPP with perioperative chemotherapy was better than EPP alone, raises the issue whether performing a P/D with perioperative chemotherapy would result in a further improvement of outcome with a lower operative mortality than with EPP and perioperative chemotherapy. This is the rationale for the next European Organisation for Research and Treatment of Cancer trial exploring the feasibility of P/D with perioperative chemotherapy.}},
  author       = {{Hiddinga, Birgitta I and Van Meerbeeck, Jan}},
  issn         = {{1556-0864}},
  journal      = {{JOURNAL OF THORACIC ONCOLOGY}},
  keywords     = {{Multimodality treatment,Lung-sparing procedures,MALIGNANT-PLEURAL-MESOTHELIOMA,EXTRAPLEURAL PNEUMONECTOMY,Extended pleurectomy/decortication,Malignant pleural mesothelioma,Extrapleural pleuropneumonectomy,PROGNOSTIC-FACTORS,LUNG-CANCER,INTERNATIONAL-ASSOCIATION,SURGICAL-MANAGEMENT,TRIMODALITY THERAPY,MULTICENTER TRIAL,PHASE-III,PLEURECTOMY/DECORTICATION}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{525--529}},
  title        = {{Surgery in mesothelioma: where do we go after MARS?}},
  url          = {{http://doi.org/10.1097/JTO.0b013e31828353d7}},
  volume       = {{8}},
  year         = {{2013}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: